Hedge Fund and Insider Trading News: David Tepper, Blue Harbour Group, ValueAct Capital, Schmitt Industries, Inc. (SMIT), Continental Resources, Inc. (CLR), and More

Blue Harbour Unloads Its Largest Position (Institutional Investor)
Here is how the activist hedge fund fared with its investment in Investors Bancorp, which accounted for 18 percent of its U.S. long assets. Cliff RobbinsBlue Harbour Group earlier this week unloaded its entire stake in Investors Bancorp – which accounted for 18 percent of the activist hedge fund’s U.S. long portfolio – in a single trade. It’s a decisive end to a long-running trade that turned out to be just a so-so performer for the activist hedge fund firm, which is having an otherwise strong year. Blue Harbour’s long-only strategy has gained about 29 percent this year through November. This compares with an 18 percent return for the Russell 2000 Value index, the hedge fund’s chosen benchmark, according to a person familiar with the results.

Billionaire Hedge Fund Manager Wins Charlotte MLS Franchise for $325M Expansion Fee (GeekyMint.com)
Earlier in the week, a leading sports hedge fund manager also known for his billionaire status, David Tepper was formally rewarded with the 30th franchise of Major League Soccer. MLS believes that the move to award its 30th franchise to the famous hedge fund manager, Tepper and city of Charlotte will massively increase the league’s rapid pace of growth. In order to secure the winning bid, the leading sports hedge fund manager, Tepper agreed to pay a record expansion fee of $325 million. The new Charlotte franchise which is yet to be named is all set to play at Bank of America Stadium in the 2021 season.

Hedge Funds: ValueAct Capital Gets Access to Confidential Citi Information for Another Two Years (DailYalts.com)
In return, ValueAct will support Citi’s board and management. ValueAct Capital, one of the most followed activist hedge funds in the industry, first engaged with Citi in early 2018. Back then, ValueAct Capital acquired a stake in Citi, which is currently 1.3%. In January 2019, Citi and ValueAct entered an Information Sharing and Engagement Agreement valid through December 2019. The parties have revalidated the agreement for another two years. The agreement allows for ValueAct to “have access to confidential information about the company and engage with members of Citi’s management team and Board of Directors on areas such as strategy, governance, and operational planning matters.”

stock, market, buy, graph, risk, trading, dice, concepts, chart, objects, investment, opportunity, business, three-dimensional, horizontal, line, gambling, decisions, symbol,

Maxx-Studio/Shutterstock.com

HFR: Hedge Fund Liquidations Outpaced Launches in Q3 (Pensions&Investments)
Hedge fund liquidations outpaced launches for the fifth consecutive quarter, data released Friday from Hedge Fund Research show. HFR said 141 managers liquidated their funds in the third quarter, compared with 186 in the second quarter and 174 in the third quarter of 2018. Hedge fund launches, meanwhile, totaled 102 in the quarter ended Sept. 30, compared with 153 launches in the previous quarter and 144 in the third quarter of 2018.

A Vintage Year for the Asgard Funds (Hedge Nordic)
London (HedgeNordic) – With the credit strategy up 26% and the fixed income strategy up close to 9%, 2019 has been another strong year for the Asgard funds. “The funds, which are fully hedged against outright movements in interest rates, have not benefitted directly from falling interest rates this year, but they have benefitted from the benign behavior of the targeted risk premia during the period”, says Moma Advisors CEO, Birger Durhuus.

Hedge Fund Killjoys Shun Reflation Trade That’s Sweeping Stocks (Bloomberg)
Bets on faster economic growth are suddenly all the rage in the equity market. But one group of sophisticated investors is sitting out the trade. Hedge funds have remained steadfast this year in their aversion to companies seen as most poised to benefit from a pickup in economic growth, or reflation. As of mid-December, the industry was positioned cautiously, with cyclical holdings relative to defensive shares and exposure to growth versus value stocks both hovering near five-year lows, according to prime brokerage data compiled by Morgan Stanley.

New Hedge Fund Launches Fall to Lowest Level Since 2008 (Hedge Week)
New hedge fund launches declined in Q3, reversing the trends of the first half of the year, with the number of launches falling to the lowest level since Q4 2008, despite a steady flow of European-located new launches. Launches totalled an estimated 102 in Q3 2019, bringing the YTD total to 391 new funds, according to the latest HFR Market Microstructure Report, released today by HFR, the established global leader in the indexation, analysis and research of the global hedge fund industry. The YTD launch total puts the industry on pace to fall below 500 new launches for 2019, which would represent the lowest annual total for new funds since 328 funds launched in 2000.

The Executive Vice Chairman* of Chubb (NYSE: CB) is Selling Shares (Analyst Ratings)
Today, the Executive Vice Chairman* of Chubb (CB), John Keogh, sold shares of CB for $4.05M. Following John Keogh’s last CB Sell transaction on October 12, 2018, the stock climbed by 31.6%. In addition to John Keogh, one other CB executive reported Sell trades in the last month.

Schmitt Industries Inc (SMIT) CEO Michael R. Zapata Bought $401,232 of Shares (Guru Focus)
CEO of Schmitt Industries Inc., Michael R. Zapata bought 123,456 shares of SMIT on 12/17/2019 at an average price of $3.25 a share. The total cost of this purchase was $401,232. Schmitt Industries Inc designs, manufactures and sells computer-controlled vibration detection, balancing and process control systems for the machine tool industry, particularly for grinding machines. Schmitt Industries Inc has a market cap of $15.020 million; its shares were traded at around $3.66 with and P/S ratio of 1.08. GuruFocus has detected 3 severe warning signs with Schmitt Industries Inc.

Latest Plot Twist: Pension Fund Sues Xerox Majority Shareholder Carl Icahn for Buying HP Stock (PiWorld.com)
With the M&A battle still waging between Xerox Holdings and HP Inc., majority Xerox shareholder and activist investor Carl Icahn, and an investment vehicle he controls, are being sued by a pension fund that is also a shareholder in Xerox. According to Bloomberg, the Miami Firefighters and Pension Fund filed a lawsuit in Manhattan on Dec. 13, claiming that Xerox board member Icahn, Icahn Capital, and High River Limited Partnership, breached their fiduciary duties when they acquired $1.2 billion worth of HP stock. The suit alleges that Icahn knew Xerox was contemplating an unsolicited $33.5 billion stock-and-cash offer to acquire HP — a proposal that ultimately valued HP stock at a premium of $22 per share.

50 Ways to Leave Your Hedge Fund (Bloomberg)
Quitting is never easy — especially for the alpha types who make up the $3 trillion hedge fund industry. Yet some of the best-known founders have thrown in the towel this year after fortune-making decades in the business.These traders all had their own reasons to hang it up. But there were some common factors behind the decisions: the challenge of competing with an ever-rising stock market, the difficulty of raising enough assets and, for many, the march of time. As 63-year-old Jonathan Kolatch told investors earlier this month when announcing his retirement: “If I don’t step away now, it’s not clear I will ever get away from my desk.”

What Did This CEO Just Do with Personal Shares of Continental Resources (NYSE: CLR)? (Analyst Ratings)
Yesterday, the CEO & Chairman of Continental Resources (CLR), Harold Hamm, sold shares of CLR for $60.27M. This is Hamm’s first Sell trade following 14 Buy transactions.

Dicerna Pharmaceuticals Inc (DRNA) CEO Douglas Fambrough Sold $3.6 million of Shares (Guru Focus)
CEO of Dicerna Pharmaceuticals Inc., Douglas Fambrough, sold 139,021 shares of DRNA on 12/18/2019 at an average price of $26 a share. The total sale was $3.6 million. Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections.